Article
Endocrinology & Metabolism
Yvonne Schnaars, Sumedh Gaikwad, Ulrike Gottwald-Hostalek, Wolfgang Uhl, Olga Ribot, Kanthikiran V. S. Varanasi, Laura Rodriguez, Javier Torrejon, Luis Gomez
Summary: Three studies compared the bioequivalence of new generic tablet formulations of sitagliptin and the fixed-dose combination of sitagliptin/metformin in healthy volunteers. The results showed that the new products demonstrated bioequivalence to the reference products, indicating similar efficacy and tolerability in the treatment of patients with type 2 diabetes.
Article
Endocrinology & Metabolism
Fang Zhang, Lizhi Tang, Jing Li, Zhe Yan, Juan Li, Nanwei Tong
Summary: This study will conduct a 24-week open-label multicenter non-inferiority parallel-group RCT in Chinese adults with T2D comparing the combination therapy of pioglitazone/metformin and sitagliptin/metformin. Primary outcomes include HbA1c reduction, insulin level increase, and IR index change, while secondary outcomes focus on weight and VAT reduction, lipid profiles, and inflammatory markers. The results of this study aim to optimize treatment for Chinese adults with T2D characterized by IR.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY
(2021)
Article
Peripheral Vascular Disease
Kenichi Tsujita, Koutaro Yokote, Junya Ako, Ryohei Tanigawa, Sachiko Tajima, Hideki Suganami
Summary: This study compared the efficacy and safety of pitavastatin/ezetimibe combination therapy with pitavastatin monotherapy in patients with hypercholesterolemia. The results showed that the combination therapy significantly reduced LDL-C and total cholesterol levels, and had a similar safety profile to pitavastatin monotherapy.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS
(2023)
Article
Endocrinology & Metabolism
Ibrar Ahmed, Umar Yousaf Raja, Muhammad Umar Wahab, Tejhmal Rehman, Osama Ishtiaq, A. H. Aamir, Tahir Ghaffar, Abbas Raza, Suresh Kumar, Akhtar Sherin, Faisal Masood, Fawad Ahmad Randhawa, Ali Asghar, Sehrish Khan
Summary: This study aimed to compare the efficacy, safety, and tolerability of empagliflozin with metformin during Ramadan in comparison with sitagliptin and metformin. The results demonstrated that SGLT-2 inhibitors combined with metformin showed similar improvements in blood sugar, HbA1c, and weight compared to DPP4 combined with metformin, with no reported cases of urinary tract infection in the empagliflozin group.
BMC ENDOCRINE DISORDERS
(2022)
Article
Dermatology
L. Stein Gold, C. Paul, R. Romiti
Summary: Studies have shown that Cal/BD foam is more effective in treating psoriasis compared to other therapies, demonstrating superior efficacy over monotherapy treatments.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2021)
Article
Medicine, Research & Experimental
Rakesh K. Sahay, Richa Giri, Jayashree V. Shembalkar, Sandeep K. Gupta, Brij Mohan, Prakash Kurmi, S. Ravindra Kumar, Vinayak M. Sawardekar, Ashutosh Mishra, L. Sreenivasa Murthy, Vivek V. Arya, Abhijit R. Sonawane, Pravin N. Soni, Sandip K. Gofne, Shital R. Karnawat, Mandodari N. Rajurkar, Piyush M. Patel, Lalit K. Lakhwani, Suyog C. Mehta, Sadhna J. Joglekar
Summary: This study compared the efficacy and safety of three different fixed-dose combination drugs (dapagliflozin + sitagliptin + metformin ER, sitagliptin + metformin SR, and dapagliflozin + metformin ER) in patients with poorly controlled type 2 diabetes. The results showed that all three combinations significantly reduced HbA1c levels, but dapagliflozin + sitagliptin + metformin ER was the most effective with good safety profile.
ADVANCES IN THERAPY
(2023)
Article
Biochemistry & Molecular Biology
Jieying Liu, Dongmei Wang, Ziyan Xie, Lu Ding, Shunhua Li, Xuemei Ma, Jing Liu, Jing Ren, Cheng Xiao, Chunru Yang, Xinhua Xiao
Summary: The study assessed the protective effects of metformin and pioglitazone combination therapy on liver lipid metabolism in high-fat diet-fed mice and investigated the molecular mechanism. The results showed that the combination of pioglitazone and metformin significantly ameliorated metabolic disturbance and hepatic lipid profiles in HFD-induced mice, through regulating lipidomics profiling and RNA-seq analysis.
Review
Multidisciplinary Sciences
Desye Gebrie, Desalegn Getnet, Tsegahun Manyazewal
Summary: This study aimed to compare the cardiovascular safety and efficacy of metformin-sodium-glucose cotransporter-2 inhibitors combination therapy versus metformin-sulphonylureas combination therapy in patients with type 2 diabetes. The results showed no significant difference in all-cause mortality, serious adverse events, and adverse events between the two therapies, but a significant reduction in hypoglycemia with the former. Participants on metformin-sodium glucose cotransporter-2 inhibitors combination therapy also demonstrated greater improvements in various metabolic indicators compared to those on metformin-sulphonylureas.
SCIENTIFIC REPORTS
(2021)
Article
Pharmacology & Pharmacy
Y. Ding, Y. Liu, Y. Qu, M. Lin, F. Dong, Y. Li, L. Cao, S. Lin
Summary: Combination therapy with vildagliptin and metformin can significantly reduce blood glucose and body weight in patients with type 2 diabetes mellitus, but it increases the risk of dizziness and does not increase the risk of other adverse events.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
(2022)
Article
Pharmacology & Pharmacy
Dong Han Won, Heejun Park, Jeong-Woong Seo, Sun Woo Jang, Eun-Sol Ha, Min-Soo Kim
Summary: This study aimed to develop a fixed dose combination tablet for daily treatment of type 2 diabetes. The use of active coating technology resulted in a successful formulation with satisfactory content uniformity and stability. Comparison of in vitro release and in vivo pharmacokinetics confirmed the bioequivalence of the developed tablet with the reference drugs.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2022)
Review
Medicine, General & Internal
Nachuan Luo, Xun Jiang, Meiqi Hao, Zige Fang, Yiping Wei, Wenxiong Zhang
Summary: Netarsudil/latanoprost fixed-dose combination (FDC) appears to be superior to netarsudil or latanoprost alone in patients with glaucoma, with better ocular hypotensive effects. However, there are concerns that FDC is associated with a significantly higher incidence of adverse events specifically compared with latanoprost.
FRONTIERS IN MEDICINE
(2022)
Review
Respiratory System
Satish Chandra Kilaru, Avya Gopal Bansal, Vaishali Sandeep Naik, Meena Lopez, Jaideep Ashok Gogtay
Summary: This review summarizes the available literature on the efficacy and safety of FP/FORM in asthma and COPD patients, confirming that FP/FORM combination therapy is an effective and safe option for the treatment of persistent asthma and moderate-severe COPD.
EXPERT REVIEW OF RESPIRATORY MEDICINE
(2022)
Article
Dermatology
Y. Tada, L. Iversen, J. Koo
Summary: This article discusses the potency and absorption of fixed-dose combination Cal/BD foam, as well as the positive early efficacy and safety data associated with its utilization in the treatment of psoriasis vulgaris. Early data indicate that Cal/BD foam forms a supersaturated solution on the skin, increasing the penetration and bioavailability of Cal and BD, resulting in improved efficacy outcomes without negatively affecting safety outcomes.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Maria Lajarin-Reinares, Elia Martinez-Esteve, Eloy Pena-Rodriguez, Mariona Canellas-Santos, Sanja Bulut, Kostas Karabelas, Adam Clauss, Carles Nieto, Mireia Mallandrich, Francisco Fernandez-Campos
Summary: This study evaluated the transdermal absorption and efficacy of Tenutex against scabies and hair lice. The results showed that Tenutex completely eradicated the parasites after different exposure times, and benzyl benzoate had no cytotoxicity.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Letter
Medicine, General & Internal
Brian J. Lipworth, Rory Chan, Kirsten E. Stewart
Summary: In the MANDALA trial, Papi et al. showed that high-dose budesonide-albuterol is superior to albuterol as reliever therapy for reducing exacerbations in patients with uncontrolled moderate-to-severe asthma.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)